Gangnam Severance Hospital
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1983-04-01
- Employees
- -
- Market Cap
- -
Study on the Effects of Mutations Under Inherited Retinal Disease in Korean
Completed
- Conditions
- Inherited Retinal Dystrophy Primarily Involving Sensory RetinaInherited Retinal Dystrophy Primarily Involving Retinal Pigment Epithelium
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT03613948
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients
Not Applicable
Completed
- Conditions
- OverweightBreast CancerObesity
- Interventions
- Drug: naltrexone/bupropionBehavioral: Mediterranean Diet
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT03581630
- Locations
- 🇰🇷
GangnamSeverance Hospital, Seoul, Korea, Republic of
Magnesium Sulfate; Postoperative Nausea and Vomiting; Laparoscopic Surgery
Not Applicable
- Conditions
- Gynecologic Disease
- Interventions
- Drug: Mg (magnesium sulfate)Drug: Control (saline)
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03541915
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
Not Applicable
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: P2Y12 antagonist monotherapy
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 1452
- Registration Number
- NCT03447379
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Souel, Korea, Republic of
Validation of Phase Lag Entropy(PLE) as an Indicator of Depth of Sedation in Patients Undergoing Spinal Anesthesia
Not Applicable
- Conditions
- Surgery Requiring Spinal Anesthesia
- Interventions
- Device: apply phase lag entropy sensor
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT03319004
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
Not Applicable
Completed
- Conditions
- Resectable Pancreatic Adenocarcinoma
- Interventions
- Device: Intraoperative radiation therapy (IORT)
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03273374
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
Phase 2
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Biological: Immuncell-LC intravenous infusion using a CIK cell agent
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT03220984
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
Inflammatory Markers for Postoperative Complications in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- Conditions
- Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03218449
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients
Phase 4
Completed
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03104621
Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents
Phase 4
Completed
- Conditions
- Ischemic Heart Disease
- Interventions
- Drug: 6-month dual anti-platelet therapyDrug: 12-month dual anti-platelet therapyDevice: Zotarolimus eluting stentDevice: Biolimus eluting stent
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 1368
- Registration Number
- NCT03056118
© Copyright 2025. All Rights Reserved by MedPath